Ultimele actualizari :
29/10/2024
Anticoagulant   Tirofiban  
Injectabil
Stabilitatea in solutie Stabilitatea in amestec Factorii care influenteaza stabilitatea Compatibilitate Microunde Bibliografie pdf

Denumirea comerciala   Denumirea comerciala     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Aggrastat Arabia Saudita, Australia, Austria, Belgia, Canada, Danemarca, Elvetia, Emiratele Arabe Unite, Finlanda, Germania, Iran, Irlanda, Italia, Luxemburg, Malaezia, Marea Britanie, Norvegia, noua Zeelandă, Olanda, Polonia, Portugalia, SUA, Suedia, Turcia, Ungaria
Agrastat Argentina, Brazilia, Chilli, Columbia, Ecuador, Egipt, Franta, Maroc, Mexic, Peru, Spania, Venezuela
Thrombostat Turcia
Tirofiban Germania, Spania
Tiroprest Turcia
Welban Spania
Xtraban India
Bibliografie   Injectabil   Bibliografie : Tirofiban  
tip publicare
1071 ziar Bergquist PA, Zimmermann J, Kenney RR, Han RYH, Hunke WA.
Stability of tirofiban hydrochloride in three commonly used IV solutions and polyvinyl chloride administration sets.
Am J Health-Syst Pharm 1999 ; 56: 1627-1629.
1420 ziar Bergquist PA, Hunke WA, Reed RA, Manas D, Forsyth RJ, Kenney RR, Cook J, Holahan M.
Compatibility of tirofiban HCl with dopamine HCl, famotidine, sodium heparin, lidocaine HCl and potassium chloride during simulated Y-site administration.
J Clin Pharm Ther 1999 ; 24: 125-132.
1508 ziar Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F.
Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU.
EJHP 2015 ;22:123-124.
1512 Laborator Tirofiban (Aggrastat®) - Summary of Product Characteristics
Beacon Pharmaceuticals Ltd 2015
1600 ziar Garabito MJ, Jimenez L, Bautista J, Santos-Rubio MD, Perez Rodrigo I.
Stability of tirofiban hydrochloride in 0.9% sodium chloride injection for 30 days.
Am J Health-Syst Pharm 2001 ; 58: 1850-1851.
1603 ziar Bergquist PA, Manas D, Hunke WA, Reed RA.
Stability and compatibility of tirofiban hydrochloride during simulated Y-site administration with other drugs.
Am J Health-Syst Pharm 2001 ; 58: 1218-1223.
1611 ziar Chalmers JR, Bobek MB, Militello MA.
Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs.
Am J Health-Syst Pharm 2001 ; 58: 504-506.
1713 ziar Trissel LA, Saenz CA.
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 311-315.
2004 ziar Patel K, Hursting MJ.
Compatibility of argatroban with abciximab, eptifibatide, or tirofiban during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 1381-1384.
3823 ziar Juan E.P, Palau M.M, Cerd? S.A, Rubert M.A, Nicolau B.R.
Compatibilité physique de médicaments administrés dans l’unité de soins intensifs
Pharmactuel 2015 ; 48, 3 : 146-152.

  Mentions Légales